688626.SH
翔宇医疗
SSE · Healthcare · Medical - Specialties · CN
CNY 41.69
−4.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 774.8M | 767.7M | 743.5M | 744.8M | 488.5M |
| Cost of Revenue | 253.1M | 256.2M | 242.3M | 233.7M | 164.8M |
| Gross Profit | 521.7M | 511.5M | 501.3M | 511.1M | 323.8M |
| Operating Expenses | |||||
| R&D Expense | 174.8M | 175.1M | 152.0M | 106.7M | 92.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 67.3M | 65.1M | 60.2M | 41.0M | 35.9M |
| Selling & Marketing Expense | 231.5M | 232.9M | 215.0M | 169.9M | 140.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 467.2M | 470.4M | 414.3M | 295.9M | 249.3M |
| Cost and Expenses | 720.3M | 726.6M | 656.5M | 529.7M | 414.0M |
| Operating Income (EBIT) | 77.5M | 76.7M | 108.5M | 244.6M | 135.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 75.9M | 74.4M | 107.2M | 244.0M | 133.0M |
| Income Tax Expense | (2.6M) | (1.6M) | 4.4M | 15.7M | 9.7M |
| Bottom Line | |||||
| Net Income | 80.5M | 78.2M | 102.9M | 227.1M | 125.5M |
| Earnings from Cont. Ops | 78.5M | 76.0M | 102.9M | 228.3M | 123.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 80.5M | 78.2M | 102.9M | 227.1M | 125.5M |
| Per Share | |||||
| Basic EPS | CN¥0.52 | CN¥0.51 | CN¥0.66 | CN¥1.44 | CN¥0.79 |
| Diluted EPS | CN¥0.52 | CN¥0.60 | CN¥0.69 | CN¥1.46 | CN¥0.79 |
| Revenue Per Share | CN¥4.90 | CN¥5.01 | CN¥4.77 | CN¥4.72 | CN¥3.08 |
| Shares | |||||
| Basic Shares Outstanding | 158.3M | 153.2M | 156.0M | 157.7M | 158.8M |
| Diluted Shares Outstanding | 158.3M | 153.2M | 156.0M | 157.7M | 158.8M |
| Profitability Metrics | |||||
| EBITDA | — | 137.5M | 148.6M | 263.5M | 153.2M |
| D&A | — | 60.8M | 40.1M | 18.9M | 17.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026